Business Context and Reporting Period
Camp4 Therapeutics Corp (CAMP) filed a Form 8-K on September 9, 2025, reporting a material definitive agreement and significant corporate governance changes. The Company is an emerging growth company developing therapies for SYNGAP1-related disorders.
Key Financial Metrics and Transaction Details
The filing details a private placement transaction structured in two potential closings:
- Initial Closing: Anticipated on or about September 11, 2025. The Company will sell 26,681,053 shares of Common Stock at $1.53 per share and pre-funded warrants for 6,003,758 shares at $1.5299 per warrant. Management will purchase an additional 36,361 shares at $1.65 per share.
- Initial Proceeds: Approximately $50.1 million in gross proceeds before fees and expenses.
- Second Closing (Contingent): Up to an additional $50.1 million in gross proceeds is available if specific triggers are met. This includes selling up to 32,721,172 shares or pre-funded warrants at the same pricing as the Initial Closing.
- Second Closing Triggers: Requires (i) regulatory clearance to commence a clinical trial for the Company's SYNGAP1 candidate, and (ii) either a 10-day volume-weighted average price (VWAP) of $7.50 or a waiver of the price threshold by majority investors.
The filing does not provide current revenue, profit, cash flow, or debt metrics, as this is a current report focused on a specific transaction rather than a periodic financial statement.
Material Changes and Governance
Significant changes to the Board of Directors and executive leadership were announced:
- Board Resignations: James Boylan, Ravi Thadhani, M.D., and Paula Ragan, Ph.D. resigned from the Board effective September 9, 2025.
- New Leadership: Douglas Williams, PhD, was appointed Chair of the Board. Daniel Tardiff, PhD, was elevated to Chief Scientific Officer, effective October 1, 2025.
- Management Participation: CEO Josh Mandel-Brehm, CFO Kelly Gold, CMO Yuri Maricich, and co-founders Richard Young and Leonard Zon participated in the Initial Closing by purchasing shares at a premium price ($1.65).
Outlook, Risks, and Contingencies
Outlook: The Company's ability to raise the full $100.2 million potential capital depends on achieving a clinical trial application clearance and maintaining a stock price of at least $7.50 (or obtaining a waiver).
Risks and Contingencies:
- Registration Rights: The Company must file registration statements within 60 days of the Initial Closing and 30 days of any Second Closing. Failure to do so may result in cash penalties.
- Dilution: The issuance of shares and pre-funded warrants will result in significant dilution to existing shareholders.
- Beneficial Ownership Limits: Pre-funded warrants cannot be exercised if the holder's beneficial ownership would exceed 19.99%.
- Market Conditions: The Second Closing is contingent on market performance (VWAP threshold), which is outside the Company's direct control.
Investor Verification Checklist
- Verify the exact closing date of the Initial Closing and the final net proceeds after placement agent fees.
- Confirm the status of the clinical trial application for the SYNGAP1-related disorder candidate to assess the likelihood of the Second Closing.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and representations.
- Monitor the stock price performance over the 30-day measurement period following the clinical trial announcement to determine if the $7.50 VWAP threshold is met.
- Check for the filing of the Initial Registration Statement within the required 60-day window to avoid penalties.